Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: ENETs and UKINETs Guidelines emphasize that patients with NETs should be referred to NET specialist clinics (NSC) and these clinics should use a multidisciplinary team (MDT) for decision making. In Belfast there has been an NSC for several decades and an MDT since 2000.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author: Ardill J
Authors: Ardill J, McCance D, Johnston B,
Keywords: NET Clinics,
Introduction: Incidence of NETs is quoted to be 2/100,000 with approximately 25% being tumors of the midgut, (0.5/100,000). Incidence is increasing. However, this may be in part due to improved diagnosis but it is also thought to be a true increase.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author: Ardill J
Authors: Ardill J, Johnston B, Stronge W, Turner G, McCance D,
Keywords: MGC,
Introduction: Increased incidence of second malignancy is observed in NETs (Kamp et al 2012).
Conference: 10th Annual ENETSConcerence (2013)
Presenting Author: Ardill J
Authors: Ardill J, Johnston B, Stronge W, Turner G, McCance D,
Keywords: second malignancy, MGC,colon cancer,
#580 Diagnostic Performance of Dual Tracer PET/CT in Staging Neuroendocrine Tumors of the Lung
Introduction: Different positron emission tomography/computed tomography (PET/CT) tracers may be useful in staging lung neuroendocrine tumors (LNETs)
Conference:
Presenting Author:
Authors: Treglia G, Stefanelli A, Cardillo G, Lococo F, Rindi G,
Keywords: Neuroendocrine tumors, lung carcinoids, PET/CT,
Introduction: Carcinoid heart disease (CHD) affects up to 15-70% of patients with carcinoid disease. Recent ENETS guidelines recommend regular echocardiographic assessment to screen for CHD. Chromogranin A (CgA) is a peptide widely used to monitor carcinoid disease progression. Neurokinin A is a tachykinin which may be a more sensitive measure of carcinoid disease progression and prognosis. N-terminal pro Brain Naturetic Peptide is used as a screening tool for heart failure and recent results suggest utility in the diagnosis of CHD.
Conference: 7th Annual ENETSConcerence (2010)
Presenting Author:
Authors: Wong C, Burgess M, Banks M, Ardill J, Poston G,
Keywords: carcinoid disease, chromogranin A, Neurokinin A, N-Terminal Barin Naturetic Peptide, carcinoid heart disease, echocardiography,